Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

NeuroPace sg&a expenses from 2020 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

NeuroPace SG&A Expenses 2020-2025 | NPCE

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

NeuroPace sg&a expenses from 2020 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Intuitive Surgical (ISRG)	$171.9B
Thermo Fisher Scientific (TMO)	$161.4B
Alcon (ALC)	$45.6B
Edwards Lifesciences (EW)	$42B
IDEXX Laboratories (IDXX)	$33.3B
DexCom (DXCM)	$26.9B
IQVIA Holdings (IQV)	$25.4B
STERIS (STE)	$21.8B
Mettler-Toledo (MTD)	$20.9B
Waters (WAT)	$19.1B
SONOVA HOLDING (SONVY)	$17.3B
Fresenius Medical Care AG KGaA (FMS)	$13.9B
Hologic (HOLX)	$12.9B
Sysmex ADR (SSMXY)	$11.8B
Penumbra (PEN)	$10.7B
Globus Medical (GMED)	$9.8B
Masimo (MASI)	$8.2B
Teleflex (TFX)	$6B
Glaukos (GKOS)	$5.2B
Integer Holdings (ITGR)	$4.1B
TransMedics (TMDX)	$3B
PROCEPT BioRobotics (PRCT)	$2.9B
Veracyte (VCYT)	$2.4B
Nihon Kohden (NHNKY)	$2.1B
LivaNova (LIVN)	$1.9B
Elekta AB (EKTAY)	$1.9B
Alphatec Holdings (ATEC)	$1.5B
Integra LifeSciences Holdings (IART)	$1.2B
Pulse Biosciences (PLSE)	$1.2B
Tandem Diabetes Care (TNDM)	$1.1B